Open AccessCharacterizing the outcomes of metastatic papillary renal cell carcinoma
Author(s) -
Connor Wells John,
Donskov Frede,
Fraccon Anna P.,
Pasini Felice,
Bjarnason Georg A.,
Beuselinck Benoit,
Knox Jennifer J.,
Rha Sun Young,
Agarwal Neeraj,
Bowman Isaac Alex,
Lee JaeLyun,
Pal Sumanta K.,
Srinivas Sandy,
Scott Ernst Douglas,
Vaishampayan Ulka N.,
Wood Lori A.,
Simpson Robin,
De Velasco Guillermo,
Choueiri Toni K.,
Heng Daniel Y. C.
Publication year - 2017
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1048
Subject(s) - medicine , renal cell carcinoma , papillary carcinoma , oncology , clear cell renal cell carcinoma , pathology , urology , thyroid carcinoma , thyroid
Outcomes of metastatic papillary renal cell carcinoma ( pRCC ) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma ( mRCC ) in the International mRCC Database Consortium ( IMDC ) were retrospectively analyzed. Outcomes were compared between clear cell (cc RCC ; n = 5008) and papillary patients ( n = 466), and recorded type I and type II papillary patients ( n = 30 and n = 165, respectively). Overall survival ( OS ), progression‐free survival ( PFS ), and overall response rate ( ORR ) favored cc RCC over pRCC . OS was 8 months longer in cc RCC patients and the hazard ratio of death was 0.71 for cc RCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months ( P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk ( OS = 34.1 months), intermediate risk ( OS = 17.0 months), and poor‐risk groups ( OS = 6.0 months). pRCC patient outcomes were inferior to cc RCC , even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.